Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 4;11(5):1417.
doi: 10.3390/jcm11051417.

Breast Cancer and Atrial Fibrillation

Emanuela Mauro  1 , Fabiana Lucà  2 , Cecilia Tetta  1 , Orlando Parise  1 , Iris Parrini  3 , Gianmarco Parise  1 , Carmelo Massimiliano Rao  2 , Francesco Matteucci  1 , Linda Renata Micali  1 , Michele Massimo Gulizia  4   5 , Mark La Meir  6 , Sandro Gelsomino  1   6
Affiliations
Review

Breast Cancer and Atrial Fibrillation

Emanuela Mauro et al. J Clin Med. .

Abstract

This study aims to establish the incidence of atrial fibrillation (AF) in breast cancer (BC) patients, focusing on staging and anti-cancer treatment. A meta-analysis was conducted to investigate the incidence of AF in BC patients and compare this incidence to other cancers. Furthermore, we evaluated the occurrence of AF as an adverse effect of biological therapies vs. non-biological therapies vs. biological therapies + non-biological therapies in BC. Finally, we compared the incidence of AF in early BC and metastatic BC. Thirty studies were included. Twenty-two studies focused on BC, encompassing 166,271 patients. In the BC group, 2.7% of patients developed AF, while in the "all cancer" group, 5.8% of patients developed AF. In addition, there was no difference between different types of therapies (p = 0.61) and between early and metastatic BC (p = 0.57). The type of anti-cancer therapy and the staging of BC does not influence AF's occurrence in this neoplastic disease.

Keywords: atrial fibrillation; breast cancer; cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Selection of studies.
Figure 2
Figure 2
Forest plot of AF incidence in breast cancer and in other types of cancer.
Figure 3
Figure 3
Forest plot of AF incidence in non-biological therapy vs. biological therapy vs. biological + non-biological therapy.
Figure 4
Figure 4
Forest plot of AF incidence Early Breast Cancer (BC) vs. Metastatic BC.
See this image and copyright information in PMC

References

    1. Yuan M., Zhang Z., Tse G., Feng X., Korantzopoulos P., Letsas K.P., Yan B.P., Wu W.K.K., Zhang H., Li G., et al. Association of Cancer and the Risk of Developing Atri-al Fibrillation: A Systematic Review and Meta-Analysis. Cardiol. Res. Pract. 2019;2019:8985273. doi: 10.1155/2019/8985273. - DOI - PMC - PubMed
    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G., Dilaveris P.E., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) Eur. Heart J. 2020;2:373–498. - PubMed
    1. Jakobsen C.B., Lamberts M., Carlson N., Lock-Hansen M., Torp-Pedersen C., Gislason G.H., Schou M. Incidence of atrial fibrillation in different major cancer subtypes: A Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19:1105. doi: 10.1186/s12885-019-6314-9. - DOI - PMC - PubMed
    1. Conen D., Wong J.A., Sandhu R.K., Cook N.R., Lee I.-M., Buring J.E., Albert C. Risk of Malignant Cancer Among Women with New-Onset Atrial Fibrillation. JAMA Cardiol. 2016;1:389–396. doi: 10.1001/jamacardio.2016.0280. - DOI - PMC - PubMed
    1. Farmakis D., Parissis J., Filippatos G. Insights into onco-cardiology: Atrial fibrillation in cancer. J. Am. Coll. Cardiol. 2014;63:945–953. doi: 10.1016/j.jacc.2013.11.026. - DOI - PubMed

LinkOut - more resources